Long-Term Management of the Carcinoid Syndrome Treatment with octreotide alone and in combination with alpha-interferon

References

• Williams E D, Sandler M. The classification of carcinoid tumors. Lancet 1963; 1: 238–9
   PubMed Web of Science ®Google Scholar
• Öberg K, Funa K, Aim G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309: 129–33
   PubMed Web of Science ®Google Scholar
• Grahame-Smith D G. The carcinoid syndrome. William Heinemann Medical Books Ltd, London 1972
   Google Scholar
• Norheim I, Theodorsson-Norheim E, Brodin E, et al. Tachykinins in carcinoid tumors; Their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metabol 1986; 63: 605–12
   PubMed Web of Science ®Google Scholar
• Jaffe B M. Prostaglandins and serotonin: Nonpeptide di-arrheogenic hormones. World J Surg 1979; 3: 565–78
   PubMedGoogle Scholar
• Norheim I, Oberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumors; an analysis of 103 patients with regard to tumor localization, hormone production and survival. Ann Surg 1987; 206: 115–25
   PubMed Web of Science ®Google Scholar
• Moertel C G, Sauer W G, Dockerty M B, et al. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14: 901–12
   PubMed Web of Science ®Google Scholar
• Moertel C G, Hanley J A. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979; 2: 327–34
   PubMedGoogle Scholar
• Kelsen D P, Cheng E, Kemeny N, et al. Streptozotocin and Adriamycin in the treatment of apud tumors (carcinoid, islet cell and medullary carcinomas of the thyroid). Proc Am Assoc Cancer Res 1982; 23: 433
   Google Scholar
• Öberg K, Norheim I, Lundqvist G, et al. Cytotoxic treatment in patients with malignant carcinoid tumors; response to streptozocin—alone or in combination with 5-FU. Acta Oncol 1987; 26: 429–32
   PubMed Web of Science ®Google Scholar
• Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77–9
   PubMed Web of Science ®Google Scholar
• Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1495–501, 1556–63
   PubMed Web of Science ®Google Scholar
• Frolich J C, Bloomgarden Z T, Oates J A, et al. The carcinoid flush: provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 1978; 299: 1055–7
   PubMed Web of Science ®Google Scholar
• Thulin L, Samnegard H, Tyden G, et al. Efficacy of somatostatin in a patient with carinoid syndrome. Lancet 1978; 2: 43
   PubMed Web of Science ®Google Scholar
• Bauer W, Briner U, Doepfner W, et al. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133–40
   PubMed Web of Science ®Google Scholar
• Kvols L K, Moertel C G, O'Connell M J, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663–6
   PubMed Web of Science ®Google Scholar
• Gorden P, Comi R J, Maton P N, et al. Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Int Med 1989; 110: 35–50
   PubMed Web of Science ®Google Scholar
• Vinik A, Moattari A R. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989; 34: 14S–27S
   PubMed Web of Science ®Google Scholar
• Tamm I, Jasny B R, Pfeffer L M. Antiproliferative action of interferons. Mechanisms of interferon actions, L M Pfeffer. CRC Press Inc, Boca Raton 1987; 2: 25–58
   Google Scholar
• Öberg K, Norheim I, Lind E, et al. Treatment of malignant carcinoid tumors with human leukocyte interferon; Long-term results. Cancer Treat Rep 1986; 70: 1297–304
   PubMedGoogle Scholar
• Öberg K, Aim G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon alpha-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. JNCI 1989; 81: 531–5
   PubMed Web of Science ®Google Scholar
• Moertel C G, Rubin J, Kvols L K. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 1989; 7: 865–8
   PubMed Web of Science ®Google Scholar
• Bogden A E, Taylor J E, Moreau J-P, et al. Response of human lung tumor xenografts to treatment with a somatostatin analogue (Somatuline). Cancer Res 1990; 50: 4360–5
   PubMed Web of Science ®Google Scholar
• Wahlund K G, Edlen B. Simple and rapid determination of 5-hydroxyindole-3-acetic acid in urine by direct injection on a liquid chromatographic column. Clin Chim Acta 1981; 110: 71–6
   PubMed Web of Science ®Google Scholar
• Wynick D, Anderson J V, Williams S J, et al. Resistance of metastatic pancreatic endocrine tumors after long-term treatment with the somatostain analogue octreotide (SMS 201–995). Clin Endocrinol 1989; 30: 385–8
   PubMedGoogle Scholar
• Lamberts S WJ, Reubi J-C. The use of sandostatin in insulinomas. The relation between in vivo responses, the presence of somatostatin receptors and the development of tachyphylaxis. Sandostatin in the treatment of GEP endocrine tumors, T M O'Dorisio. Springer-Verlag. 1987; 39–42
   Google Scholar